CONMED Corp — Form 8-K
Filed July 29, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 48/100
What the filing says
CONMED reported Q2 2026 sales of $343.5M (flat YoY as reported; +6.0% organic constant currency excluding GI divestitures). Diluted EPS was $0.77 GAAP (+11.6% YoY) and $1.38 adjusted (+20.0% YoY), including $0.21 tariff refund benefit. The company raised full-year 2026 adjusted EPS guidance to $4.48–$4.60 (midpoint $4.54, +2.1% vs. prior midpoint $4.375) and organic constant currency growth to 5.0–6.0% (from 5.0–6.5%). Leadership changes: CFO John Gallagher appointed (July 15); board members Celine Martin and Jeff Mirviss appointed (July 1). AirSeal Robotic Solution cleared for da Vinci 5 platform (July 22).
Why this rating
Modest EPS guidance raise (~2%) and organic growth deceleration offset by operational progress; meaningful but not transformational relative to $1.2B market cap.
See more from July 29, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.